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A monoclonal antibody, K9/9, directed against a novel epithelial cell
surface sialo-glycoprotein, SGP-115/107, present in the rat glomerulus,
has been shown to induce glomerular epithelial cell effacement and
retraction, and an increase in protein excretion rate upon in vivo
administration. Such damage is not seen upon administration of two
additional monoclonal antibodies that recognize this epithelial cell
antigen, but with different epitope specificities. To further clarify the
mechanism of the epithelial cell abnormality, in vitro studies were
performed on glomerular epithelial cells established in primary culture.
None of these antibodies alone appeared to induce alterations in the
cultured cells. However, an antibody of the IgG2a isotype induced
complement-dependent cell damage in vitro, although failed to be
pathogenic when administered in the intact animal. The pathogenic
potential of K9/9 cannot be attributed to its isotype or rates of
association or dissociation from the antigen. Studies suggest that all
three monoclonal antibodies recognize different, though spatially close
epitopes on SGP-l 15/107. These results demonstrate, for the first time,
a complement- and leukocyte-independent mechanism of tissue injury
that results from an epitope-specific interaction between a monoclonal
antibody and its specific, epithelial cell surface-antigen. Results ob-
tained in other cell systems suggest that abnormalities of epithelial cell
structure and function can result from the interaction between specific
cell surface components, particularly growth factor receptors, and
monoclonal antibodies that mimic the actions of the specific agonist.
Although a number of non-immune mechanisms of glomeru-
lar injury appear to play a key role in the progression of
established renal diseases in humans and experimental animals
[I], the great majority of primary glomerulopathies are caused
by an immune mechanism. Such diseases usually involve either
exogenous antigens entrapped in the glomerular capillary wall.
which subsequently become the target of an appropriately-
evoked immune response, or endogenous antigens to which the
organism becomes sensitized by an abnormality in the immune-
regulatory mechanisms that, under normal circumstances, pre-
vent the development of autoimmunity 12].
In many glomerular diseases, the damage to the glomerular
microvasculature occurs through the deposition of antibodies
and is mediated either by lytic components of the activated
complement system [3, 4], by triggering the coagulation cascade
[5], or via inflammatory cells attracted to the glomerular capil-
lary wall by gradients of locally-released chemotactic agents [6,
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7]. There remain, however, a certain proportion of glomeru-
lopathies, most notably minimal change disease and closely
related conditions, that do not appear to be mediated by any of
the above-mentioned systems of tissue injury. The observation
of early and persistent recurrent disease that affects allograft
recipients in some of the more aggressive forms of these
glomerulopathies [8—10] has led investigators to postulate the
existence of circulating factors that would mediate or induce the
structural and functional glomerular abnormalities. Clearly,
other mechanisms, as yet poorly characterized, must be in-
volved in the induction of structural alterations of the glomer-
ular visceral epithelial cell that accompanies the striking per-
meability changes observed in these disorders. The search for
such factors and investigations on potential mechanisms of cell
injury by systems other than those summarized above have for
the most part remained fruitless.
In this study we describe a novel mechanism of glomerular
epithelial cell injury that critically depends on an epitope
specific interaction between a cell surface moiety and a mono-
clonal antibody. The mechanism of cell damage does not
involve the classical mediators of immune injury and resembles
the changes induced directly in other cell systems by antibodies
or specific agonists for cell surface receptors.
Methods
Animals
Female Lewis rats were purchased from Charles River Breed-
ing Laboratories (Wilmington, Massachusetts, USA) and al-
lowed free access to food and water. Female BALB/c mice,
eight weeks old, were obtained from Cumberland View Farms
(Clinton, Tennessee, USA) and fed ad libitum.
Production and characterization of monoclonal antibodies
Monoclonal antibodies directed at epithelial cell surface
antigens were produced as described previously [11]. Class and
subclass were determined by double diffusion in agar using
commercially prepared antisera (ICN ImmunoBiologicals, Lisle,
Illinois, USA). The binding patterns of these monoclonal anti-
bodies to tissues of the rat were determined on 4 tm thick
acetone-fixed tissue sections using hybridoma supernatants and
fluorescein conjugated, affinity-purified rabbit anti-mouse im-
munoglobulin as previously described 112].
The ability of these monoclonal antibodies to bind comple-
ment in vitro was assessed using an immunofluorescence tech-
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nique on fixed sections of rat kidney 112, 13] and alytic assay on
affinity purified cultures of rat proximal tubule epithelial cells or
glomerular epithelial cells as described below.
To obtain large quantities of monoclonal antibodies for in
vivo administration to rats, the hybridoma cells were injected
into mice previously primed with 2,6,10,14-tetramethyipenta-
decane (Aldrich Chemical Company, Milwaukee, Wisconsin,
USA). The ascites fluid was collected, subjected to a 45%
ammonium sulfate precipitation, and the resulting immunoglob-
ulin fraction was dialyzed against PBS for two to three days and
against saline for one day. The protein solution was removed
from dialysis, subjected to ultrafiltration, and stored at —70°C
until used. The antibody preparations were labeled with 12S1 by
the chloramine T technique [13] or with lodobeads (Pierce
Chemical Company, Rockford, Illinois), following the manufac-
turer' s recommendation.
Animal experiments
Normal Lewis rats received monoclonal antibodies contained
in 10 to 40 mg of ascitic protein by an intravenous route and a
subcutaneous injection of 0.2 ml of Freund's adjuvant contain-
ing 5 mg/mI H37 RA Mycobacterium tuberculosis (Difco Lab-
oratories, Detroit, Michigan, USA) and I mg of ascites derived
non-kidney binding immunoglobulin. Rats were housed in met-
abolic cages with free access to food and water. Urinary protein
levels were determined using the sulfosalicylic acid precipita-
tion method 1131 with human serum (Lab-Trol, Dade Diagnos-
tics, Aguada, Puerto Rico) serving as protein standards. Differ-
ences in urinary excretion within experimental groups was
assessed by paired t-test for statistical significance. Differences
among the three experimental groups were studied by one-way
analysis of variance followed by multiple pairwise comparisons.
Animals were sacrificed 24 or 48 hours after antibody admin-
istration. The right kidney was removed under Nembutal anes-
thesia, and coronal sections were placed in 10% formalin or
snap frozen in liquid nitrogen. The left kidney was perfused in
situ with 1.25% glutaraldehyde and processed for light and
electron microscopy as previously described [12]. Frozen sec-
tions of the right kidney were processed (unfixed) for direct
immunofluorescence microscopy (DIF) using fluorescein con-
jugated, affinity-purified rabbit anti-mouse immunoglobulin, af-
finity-purified rabbit anti-rat immunoglobulin, and goat anti-rat
C3, as previously described [12]. Formalin fixed portions of the
unperfused (right) and perfused (left) kidneys were embedded in
paraffin, and 3 m sections were stained with hematoxylin-
eosin or periodic acid-Schiff reagent (PAS) and examined for
hypercellularity and structural abnormalities.
The amount of antibody bound in vivo was determined with
'251-labeled immunoglobulin, as described previously 113].
Twenty-four hours after antibody administration, the right
kidney was removed under anesthesia and processed for mor-
phologic and immunofluorescence studies as described above.
The left kidney was perfused with PBS in situ, removed, and
the radioactivity of the tissue measured. The amount of glomer-
ular-bound immunoglobulin was calculated by the method
described by Salant, Darby and Couser [14], assuming a total
glomerular count of 38,000/kidney.
Antigen and epitope specf1ciries of monoclonal antibodies
The antigen and epitope specificities of the monoclonal
antibodies were established by immunoprecipitation, Western
blots, electrophoretic analysis of proteolytic peptides, compet-
itive radioimmunoassay on immobilized, proximal tubule brush
border vesicles, and by analysis of the association and disso-
ciation characteristics of the antibodies with the antigen.
Immunoprecipitation, For this procedure, glomerular and
proximal tubule brush border antigens were solubilized in
non-ionic detergent, radiolabeled with 1251, and precipitated
with affinity-purified rabbit anti-mouse lgG as described previ-
ously [13].
Western blot analysis. Glomerular and brush border antigens
were resolved by SDS-polyacrylamide gel electrophoresis. For
this purpose, sieve-isolated glomeruli or brush border vesicles
were prepared by previously described methods [13]. Then they
were solubilized in sample buffer and electrophoresed on 5 to
15% gradient gels by the discontinuous polyacrylamide gel
system described by Laemmli [IS]. Protein bands were trans-
ferred to nitrocellulose paper (Millipore Corp., Bedford, Mas-
sachusetts, USA) following the electrophoretic procedure de-
scribed by Towbin, Staehelin and Gordon [16]. The paper was
then cut into 0.8 cm wide strips, and each strip was incubated
with a monoclonal antibody. The bound murine immunoglobu-
lin was detected with 1251-labeled affinity purified, rabbit anti-
mouse immunoglobulin. Radioactive bands were visualized by
direct and indirect autoradiography [13].
Proteolytic peptide analysis. Peptide maps of the antigen
recognized by monoclonal antibodies were obtained by a mod-
ification of the protease digestion procedure described by
Cleveland et al [17]. The iodinated immunoprecipitate was
resuspended in 25 p1 of 0.4 mg/mi Staph protease (Cooper-
Biomedical, Malvern, Pennsylvania, USA) in 0.125 MTris-HCI
buffer, pH 6.8, containing 0.5% SDS and 10% glycerol. The
samples were incubated at 37°C for 30 minutes, solubilized by
boiling for five minutes in SDS sample buffer, and the superna-
tant resolved by SDS-polyacrylamide gel electrophoresis on a
15% discontinuous gel system. The gels were stained with
Coomassie Blue, destained in methanol/acetic acid, dried, and
autoradiographed as described before [13].
Competitive radioimmunoassay. This assay was performed
to further characterize the epitope specificity of the rnonoclonal
antibodies. The procedure was done following a modification of
the technique described by Ways and Parham 118]. Microtiter
plates (Dynatech Laboratories, Alexandria, Virginia, USA)
were coated overnight at 4°C with 6 g/ml of particulate rat
brush border membranes in 0.05 M carbonate buffer, pH 9.5.
The plates were washed with PBS containing 0.05 ml/100 ml of
Tween 20. Seven serial dilutions of blocking antibodies were
made in PBS containing 0.5 gIlOO ml ovalbumin. The immobi-
lized antigen preparation in each well was then incubated for
two hours at room temperature with 75 p1 of blocking antibody
in decreasing concentrations. At the end of this incubation
period, 50 p1 of the blocking antibody solution in each well were
removed and replaced with 50 p1 of the radiolabeled, test-
monoclonal antibody preparation diluted in PBS/ovalbumin to
an activity of approximately 500,000 cpm/50 p1. The incubation
was performed at room temperature for 30 minutes; the plates
were washed three times in PBS-Tween, and the wells were cut
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out and counted. Control plates were coated with a 1% vol/vol
solution of horse serum and incubated with the various dilutions
of the blocking monoclonal antibodies and the radiolabeled
test-monoclonal antibody. Under these assay conditions, the
radiolabeled antibodies did not bind to the control plate. The
level of saturation of antigenic sites achieved with the various
dilutions of blocking antibodies was determined in additional
experiments. Antigen-coated plates were incubated with the
various dilutions of blocking antibodies, washed, and incubated
with 1251-labeled affinity-purified, rabbit anti-mouse immuno-
globulin. By this procedure, all blocking antibodies were shown
to saturate the immobilized antigen at least for the three lowest
dilutions tested. Antibodies used in these competitive radioimmu-
noassays included two monoclonal antibodies (K35/9, K35/3)
directed against glycoprotein 330 (gp330) of the proximal tubule
and glomerular epithelial cell membrane, a non-binding mono-
clonal antibody (K16/16) which does not recognize renal anti-
gens, and three monoclonal antibodies with specificity for the
115/107 kd epithelial antigen, SGP-l 15/107. Unlabeled dilutions
of the test-monoclonal antibody were used as a positive block-
ing control.
Association and dissociation neasuremen1s. Relative asso-
ciation and dissociation rates for each monoclonal antibody
were determined by a modification of the techniques described
by Ways and Parham [19] and Mason and Williams [20]. For
this purpose, the NP-40-solubilized brush border antigen prep-
aration was immobilized on Sepharose CL-4B (Pharmacia, Inc.,
Piscataway, New Jersey, USA) following the manufacturer's
directions. The monoclonal antibodies were purified from as-
cites fluid by ammonium sulfate precipitation and labeled with
1251 using lodobeads. Non-specific binding and entrapment of
the radiolabeled antibody by the Sepharose was determined in
parallel experiments utilizing Sepharose coupled with a non-
specific protein (the immunoglobulin fraction of mouse ascites).
Each radiolabeled monoclonal antibody was incubated in
microfuge tubes with an excess of Sepharose-bound brush
border antigen or the Sepharose-bound control protein. The
tubes were incubated on a tube rotator at room temperature for
one hour. The Sepharose preparations were pelleted and washed
three times in PBS containing 0.1 g/l00 ml of sodium azide.
During the last wash, the Sepharose suspensions were trans-
ferred to new microfuge tubes to eliminate any background
binding of radioactive components to the walls of the tubes. The
net amount of antibody bound to its target antigen was ex-
pressed as the difference between the mean radioactivity bound
to the brush border antigen preparation and that bound to the
control protein. This amount was considered 100% of bindable
counts.
To obtain an estimate of the relative association rates be-
tween the antigen and the various monoclonal antibodies, 500
t1 of a radiolabeled antibody, containing 500,000 cpm, was
incubated on ice with 500 il of a 40% vol/vol suspension of each
Sepharose preparation in duplicate for times ranging from 2 to
14 minutes. To avoid dissociation of the antigen/antibody
complexes during repeated wash periods, a single dilution step
into 45 ml of cold PBS was performed, followed by centrifuga-
tion. Using this washing step, the background binding to the
control protein ranged between I and 2% of the added antibody.
The net amount of antibody bound at various incubation
periods was then expressed as a percentage of the value
obtained at one hour (considered as 100% bindable counts, see
above).
An estimate of the relative dissociation rates was also ob-
tained by a similar technique. For this purpose 1 ml of a 20%
vol/vol suspension of each Sepharose preparation was incu-
bated with iodinated monoclonal antibody (approximately 1 x
106 cpm) on a shaker at room temperature for 30 minutes, an
incubation time sufficient to achieve steady state binding of the
antibody to its target antigen. The Sepharose pellet was washed
as described above, transferred to a new microfuge tube and
recounted. The percentage of bound counts was calculated for
each preparation after subtracting the non-specific binding of
the radiolabeled monoclonal antibody to the Sepharose-bound
control protein. The tubes were replaced on the shaker at room
temperature and incubated for 3, 7, 24, 48, 76, 100, and 124
hours. At the end of each time period, the tubes were centri-
fuged, the supernatant aspirated, the Sepharose resuspended in
PBS/azide, and the tubes counted. All experiments were per-
formed in triplicate. Proteolysis of the immobilized antigen over
a 24 hour period at room temperature, as determined by the
capacity to bind specific monoclonal antibodies maximally, and
spontaneous loss of the antibody activity over a similar period
of incubation time at room temperature was negligible.
Cell culture experiments
Rat glomerular epithelial cells were established in primary
culture following the technique described by Harper et al [21].
Affinity purified rat, proximal tubule epithelial cells were grown
on fibronectin-coated wells of 24-well plates as previously
described by us [22]. The relative quantity of mouse immunoglo-
bulin bound to cultured cells was determined by a radioimmu-
noassay. Cells were incubated for 60 minutes with monoclonal
antibodies, washed, and exposed to '25l-labeled affinity-
purified, rabbit anti-mouse immunoglobulin for 60 minutes at
4°C. The cells were washed repeatedly, solubilized in detergent,
and the specific binding of '251-rabbit anti-mouse immunoglob-
ulin determined in a Beckman Biogamma II gamma counter
(Beckman Instruments, Inc., Irvine, California, USA). The net
amount of second antibody bound to the cells was calculated as
the difference in radioactivity of cells exposed to the specific
monoclonal antibody and cells exposed to a non-binding anti-
body of the same isotype. All quantitative values were derived
from experiments performed in triplicate.
To assess a potential pathogenic role of the monoclonal
antibodies under study, cells established in culture for three to
seven days were incubated with an antibody in the presence or
absence of a source of complement. Cell viability was estab-
lished by the degree of incorporation of radiolabeled amino
acids into cellular proteins. For these studies, cells were
washed with Hank's balanced salt solution containing 1% fcs
and 10 mri I-IEPES, pH 7.5, and were incubated at 4°C for 60
minutes in this buffer containing an immunoglobulin fraction of
ascitic fluid (final concentration of immunoglobulin = 0.2 to 0.4
mg/mI). After washing, the cells were incubated at 37°C for one
hour with normal human serum diluted 1:10 in barbital buffer
(0.005 M barbital, 0.142 M NaCI, 0.15 msi CaCI2, 0.5mM MgCl2,
pH 7.35). The cells were then washed and re-incubated for one
to three hours at 37°C in leucine-free RPMI 1640 containing 5%
fcs, 2 mst L-glutamine, 10 mivi HEPES, and 5 pCi/mI tritiated
leucine (Amersham Corporation, Arlington Heights, Illinois,
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Table I. Characteristics of monoclonal antibodies
mAb
Antigen specificity
molecular wt Class
C-binding
in vitro
Proteinuria
in vivo
K9/9
K35/4
K35/64
GCW,BB; 115/107 kd
GCW, BB; 115/107 kd
GCW, BB; 115/107 kd
IgG1
IgG2,
lgG1
—
+
—
+
—
—
K35/9
K35/3
gp330; 330 kd
gp330; 330 kd
IgG2a
lgG1
+
—
—
—
K3513l GEC; ND IgG2a + —
K16/16
El/A
negative control
negative control
IgG1
IgG2
— —
—
Abbreviations are: mAb, monoclonal antibody; GCW, glomerular
capillary wall; BB, brush border of proximal tubule epithelium; GEC,
glomerular visceral epithelial cells; gp330, glycoprotein of the coated
pits and vesicles; ND, not determined.
Fig. 1. Distribution of SGP-115/107 in the renal cortex. This immuno-
fluorescence micrograph shows the binding pattern seen with monoclo-
nal antibody K9/9. Identical results were obtained with monoclonal
antibodies K35/4 and K35/64. The antibody binds to the glomerular
capillary wall and to the brush border of the proximal tubules. (Indirect
immunofluorescence microscopy on normal rat renal cortex, x475).
USA). Cells were washed, solubilized in SDS and the incorpo-
ration of tritiated leucine measured in an LKB RackBeta
scintillation counter (LKB Instruments, Inc., Gaithersburg,
Maryland, USA) utilizing Ecofite scintillation fluid (WestChem,
San Diego, California, USA). The inhibition of protein synthe-
sis was calculated using the mean values obtained from six
cultures and expressed as a percentage of the values obtained
from cells incubated with the same antibody and heat-inactiva-
ted human serum. The inhibition of protein synthesis is a
sensitive measure of cellular dysfunction which precedes cell
death [23, 24] and was utilized in these studies to assess not
only cell death resulting from lysis but also to detect an
antibody- or complement-dependent sub-lethal effect leading to
cellular dysfunction. Control experiments, performed with the
trypan blue dye exclusion test [25], confirmed that inhibition of
protein synthesis was an objective and sensitive assay of cell
injury.
Results
Characterization of monoclonal antibodies
Three monoclonal antibodies with identical immunohistologi-
cal binding to the rat kidney were studied for their nephrotoxic
capacity and antigen/epitope specificity. K9/9 and K35/64 are of
the IgG1 isotype while K35/4 is of the IgG2 subclass. All three
antibodies bind in a diffuse fashion to the glomerular capillary
wall and along the surface of the proximal tubule brush border
(Fig. 1). Reactive antigenic sites are also present on the surface
of the intestinal brush border, on the biliary pole of the
hepatocyte, the luminal cell surface of bile ducts, and the
venules of the spleen, as described previously [13]. There is no
detectable difference among these three monoclonal antibodies
in their binding characteristics when studied by indirect im-
munohistochemical techniques. For competitive antibody bind-
ing studies on Sepharose-bound brush border antigen, we
utilized two additional monoclonal antibodies (K35/3, of the
IgG1 isotype, and K35/9, an IgG2a antibody), with specificity for
an antigen present on coated pits and vesicles located at the
base of the proximal tubule brush border and focally on
glomerular epithelial cells (Table 1). Comparative antibody-
binding studies and complement-mediated lysis experiments on
cultured cells were performed with K9/9, K35/4, K35/64, and an
additional monoclonal antibody specific for a glomerular epi-
thelial cell surface antigen (K35/31, of the IgG2 subclass). Two
monoclonal antibodies without specificity for rat tissue antigens
(Kl6/16 and El/A; Table 1) served as negative controls.
Antigen specificity of monoclonal antibodies
Monoclonal antibodies of K9/9, K35/4, and K35/64 specifi-
cally immunoprecipitate two peptide bands with apparent mo-
lecular weights of 115 and 107 kilodaltons (kd) from NP-40
solubilized glomerular antigens (SGP-1 15/107). Only the 107 kd
band is immunoprecipitated from an antigen preparation de-
rived from purified renal brush border vesicles (Fig. 2). These
findings suggest that the 115 kd peptide is of glomerular origin,
while the 107 kd antigen is likely to be derived from the
proximal tubule. Contamination of the isolated glomeruli by
proximal tubule fragments could account for the presence of the
small brush border peptide in the immunoprecipitates derived
from glomeruli. Identical proteolytic peptide bands were ob-
tained following protease digestion of the antigen(s) immuno-
precipitated by the three monoclonal antibodies (Fig. 3). Col-
lectively, these results and those reported previously 113]
indicate that monoclonal antibodies K9/9, K35/4, and K35/64
are specific for a single antigen shared by epithelial cells of
various origins, including the glomerulus and the proximal
tubule; the small difference in molecular weight between the
glomerular- and the brush border-derived component is likely to
be due to variations in the degree of glycosylation.
Monoclonal antibodies K35/9 and K35/3 immunoprecipitate a
large glycoprotein with apparent molecular weight of about 330
kd (gp330) from the solubilized brush border antigen prepara-
tion. The glomerular epithelial cell antigen recognized by K35/3 I
has not been isolated from detergent-solubilized glomeruli,
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Fig. 2. Autoradiograph of renal antigens immunoprecipitated from
detergent-solubilized brush border (lanes I to 5) and glo,nerular cell
membranes (lanes 6 to 10) by monoclonal antibodies. lodinated anti-
gens were immunoprecipitated and resolved by gradient SDS electro-
phoresis under reducing conditions. K9/9, lanes 1, 3, 6, and 8; K35/4,
lanes 2 and 7; K35/64, lanes 4 and 9; K16/16 (non-kidney reactive
monoclonal antibody), lanes 5 and 10. The three antibodies immuno-
precipitate a peptide band with a relative mobility of 107 kd from the
brush border antigen preparation while an additional 115 kd component
is identified in the immunoprecipitates from the solubilized glomeruli
(direct and indirect autoradiography).
most likely due to loss of the antigenicity of the epitope under
the conditions of immunoprecipitation.
Animal experiments
Twenty-four hours following an intravenous administration
of monoclonal antibodies K9/9, K35/4, or K35/64, all animals
exhibited mouse immunoglobulin bound to the glomerular cap-
illary wall in a diffuse and irregular pattern. Occasionally, focal
binding was also seen along the tubular basement membrane
and on the brush border of the proximal convoluted tubule (Fig.
4). Although all three monoclonal antibodies bound in a similar
pattern, only the rats which received K9/9 developed protein-
uria during the first 48-hour period post-injection (Table 2).
Abnormal urinary protein excretion was not seen in any of
the animals injected with either of two anti-gp330 antibodies,
K35131, or the two antibodies without specificity for rat tissues,
K16116 and El/A. Light microscopic examination of the renal
tissue of rats injected with any of these monoclonal antibodies
failed to demonstrate an inflammatory response. However,
ultrastructural examination of glomeruli from rats injected with
K9/9 exhibited prominent visceral epithelial cell vacuolar changes,
cell surface microvillous formation, effacement of foot pro-
cesses, and epithelial cell detachment (Fig. 5A). Focal areas of
brush border loss were noted in occasional proximal tubule
Fig. 3. Proteo!v tic peptides of immunoprecipitated proximal tubule
brush border antigen resolved by SDS-PAGE on a 15% gel. The bands
seen in lanes I, 3, 5, and 7 show undigested peptides immunoprecipi-
tated with K9/9, K35/4, K35/64, and control monoclonal antibody,
K 16/16, respectively. When these immunoprecipitated antigens were
subjected to protease digestion (lanes 2, 4, 6, and 8), identical peptide
bands were identified for the three monoclonal antibodies, K9/9, K35/4,
and K35/64. (Direct and indirect autoradiography).
Fig. 4. immunofluorescence binding pattern obtained with K9/9 upon
in vivo injection of the antibody. There is weak deposition of the
antibody in a diffuse pattern along the glomerular capillary wall. The
proximal tubule brush border also shows focal antibody staining.
(Direct immunofluorescence microscopy, x473).
kd
200-
1 2 3 4 5 6 7 8 9 10 2345678kd
116
45
31
21.5
14.4
ii'
+0
836 Mendrick and Rennke: Epitopespecfic glomerular cell injury
Table 2. Results ofanimal experiments
mAb
Injected N
Dose
mg
Urine protein
mg/24 hr?
day 0 day I day 2
K9/9 18 10 5 2 32 14b 28±6"
K35/4 6 20—40 5 1 II 7 11 4
K35164 5 10—40 6±3 9±3 8±2
a Values are means 1 SD.
b P<0.05 when compared to day 0 values or to values seen in groups
K35/4 and K35/64
Table 3. Antibody binding studies
Antibody
Dose
mg
mAb bound to
2 kidneys
mAb bound to
glomeruli
g
— -—
K9/9 10 36.5 18
K35/4 15 72,0 23
K35/64 40 258.5 48
The values are the means of two animals in each group.
Fig. 5. Glomerular ullrastructural abnormalities induced in animals injected with monoclonal antibodies directed against the 115/107 kd antigen.
A. Animal injected with K9/9. Prominent visceral epithelial cell abnormalities have developed at 24 hours, with increase in lysosomal structures,
focal obliteration of the interdigitating architecture of foot processes, surface microvillous formation, and separation of the epithelial cell from the
underlying basement membrane (arrows). These changes Were associated with an increase in the rate of urinary protein excretion. B. Animal
injected with K35/4. The ultrastructural details of the glomerular capillary wall are well preserved. Epithelial cells show only minimal microvilli
on their cell surface. These animals did not develop proteinuria. CL = capillary lumen; US = urinary space; Ep = visceral epithelial cell. (A x3500;
B x3150).
profiles. No electron dense deposits were visible along the
peripheral glomerular capillary wall, within the mesangial ma-
trix, or along the tubular basement membrane. Animals that
received injections of monoclonal antibodies K35/4 or K35/64
exhibited normal glomerular epithelial cell architecture at the
ultrastructural level. Focal microvilli were seen only sporadi-
cally on glomerular visceral epithelial cells (Fig. SB). None of
the animals exhibited rat C3 bound to renal structures, Glomer-
uli of animals injected with either the anti-gp330 antibodies
(K35/3 and K3519), the monoclonal antibody with specific
binding for glomerular visceral epithelial cells (K35131), or any
of the non-binding control antibodies (K 16/16 and El/A) did not
show epithelial cell abnormalities when examined by electron
microscopy.
We next sought to determine if the nephrotoxicity of K9/9
and the lack of glomerular injury following administration of
K35/4 and K35/64 were related to the amount of immunoglob-
ulin bound within the glomeruli. The in vivo antibody binding
studies are summarized in Table 3. Administration of 10 mg of
K9/9-containing immunoglobulin fraction to rats was associated
with proteinuria with an average of 18 g of antibody bound to
glomerular structures. Conversely, administration of 15 mg of
K35/4-containing immunoglobulin or as much as 40 mg of
K35/64 did not result in proteinuria, but on average glomerular
bound immunoglobulin levels exceeded those seen with K9/9
(Table 3).
Epitope specificities of monoclonal antibodies
Differences in epitope specificity between the three monoclo-
nal antibodies (K9/9, K35/4, and K35/64) directed at SOP-I 15/
107 were established by the results obtained from immunoblot
analyses and competitive radioimmunoassays. Of these three
monoclonal antibodies, only K9/9 was directed at an epitope on
the antigen that remained reactive following SDS denaturation,
polyacrylamide gel electrophoresis, and the electrophoretic
transblotting. As illustrated in Figure 6, the nitrocellulose strips
exposed to K35/4 or K35/64 do not show binding of the
'251-labeled affinity-purified rabbit anti-mouse immunoglobulin.
Figure 7 summarizes the results of the competitive radioimmu-
noassay performed on brush border membrane fragments. As
can be seen in Figure 7A, the binding of '251-labeled K9/9
antibody is completely blocked by an excess of the unlabeled
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Fig. 6. Western blot analysis of glomerular proteins reacted with
monoclonal antibodies. Lane I illustrates the results obtained on a
nitrocellulose strip, following incubation with monoclonal antibody
K3514, lane 2 shows the binding pattern of K9/9. Two peptides with
apparent molecular weights of 107 kd and 115 kd are recognized only by
K9/9. The SDS-denatured antigen does not bind K35/64 (lane 3). Lane
4 shows the results obtained with the control antibody K16/l6. (Direct
and indirect autoradiography).
antibody and by K35/64; only partial blocking is accomplished
with an excess of K35/4. No inhibition of binding is observed
with anti-gp330 monoclonal antibodies K35/3 and K35/9, or
with the control antibody without specificity for rat antigens,
K16/16. The radiolabeled K35/4 (Fig. 7B) shows inhibition of
binding by the unlabeled antibody preparation and by K919, but
not by K35/64. Finally, the radiolabeled K35/64 (Fig. 7C) is
blocked from binding to its antigenic site by K919 and by the
unlabeled K35164, but not by K35/4. None of these antibodies is
blocked by the binding of K35/3, K35/9, or K16/16. Taken
together, the results seen by the Western blot analyses and
those obtained by the blocking immunoassays suggest that K9/9
recognizes a distinct and unique epitope located spatially be-
tween the antigenic sites recognized by K35/4 and K35/64.
Dilution
Fig. 7. Competitive radioimmunoassay on isolated brush border vesi-
des. The amount of radio-iodinated test antibody (y-axis) bound to the
cell membrane preparation is plotted against the reciprocal value of the
dilutions of monoclonal antibodies (x-axis) used to block the binding to
the antigen. Three antibodies against the SGP-l 15/107 antigen (K9/9,
asterisks; K35/4, open circles; K35/64, open squares), two antibodies
specific for gp330 (K35/9, open triangles; and K35/3, solid squares), and
the non-binding monoclonal antibody K 16/16 (no marker) were utilized
in separate experiments to inhibit binding of '251-K9/9 (A), '251-K35/4
(B), and '251-K35/64 (C).
Properties of the antibodies
To determine if the ability of these monoclonal antibodies to
induce glomerular disease was related to their binding charac-
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Fig. 10. In vitro complement-binding capacity of monoclonal antibodies revealed on frozen sections of renal cortex. A. The pattern of human C3
deposition following pre-incubation with K35/4. Complement binding reproduces the distribution of the antigen present within the glomerular
capillary wall and on the brush border of the proximal tubules. B. The results obtained on the sections pre-incubated with 1(9/9. The minor amount
of C3 bound to tubule profiles was also present in all control slides. Similar results were obtained with monoclonal antibody K35/64 (x 190).
teristics, relative rates of association and dissociation from a
Sepharose-bound antigen preparation were estimated. The re-
suits obtained from such analyses are shown in Figures 8 and 9.
Both K35/64 and K35/4 exhibit similar or greater rates of
association with the antigen when compared to 1(9/9, as judged
from the slopes of the regression lines that summarize the
amount of antibody bound over time. The dissociation from the
antigen is somewhat slower over the first 24 hours for K9/9 and
K35/64, while K3514 dissociates more rapidly (Fig. 9). The
differences in the dissociation rates were maintained for the
various antibodies over six days. The amount of antibody
bound to the antigen at 144 hours for K35/64 corresponds to
73% of the amount measured at the beginning of the dissocia-
tion assay; for K9/9 the value is 61%, and for 1(35/4, 41%
remains bound at the end of the experiment.
To correlate the complement-binding capacity of these mono-
clonal antibodies and their in vivo nephrotoxicity, in vitro tests
on frozen tissue sections and on cultured glomerular epithelial
cell explants were performed. Following in vitro incubation of
the three monoclonal antibodies directed at SOP-I 15/107 on
tissue sections, we found that only K35/4 (an lgG2 isotype) was
capable of binding human C3 at the sites of antibody deposition
(Fig. 10, Table 1). However, this antibody did not induce
significant glomerular epithelial cell alterations or proteinuria in
0
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Fig. 8. Rate of binding of monoelonal antibodies to solubilized brush
border proteins ipn,nobilized on Sepharose beads. Lines of regression
were drawn through the points obtained for each monoclonal antibody.
K35/4 (open circles) and K35/64 (open squares) exhibit similar associ-
ation rates, as suggested by equivalent slopes of the regression lines,
while K9/9 (asterisks) displays a reduced rate of association with the
antigen.
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Fig. 9. Dissociation of monoclonal antibodies from soluhilized bruso
border proteins coupled to Sepharose beads. The plotted values are
expressed as a percentage of the amount bound at thirty minutes. 1(9/9
(asterisks) and 1(35/64 (open squares) exhibit similar rates of decline
while K35/4 (open circles) and anti-gp330 antibody, K35/9 (open trian-
gles), exhibit faster dissociation rates.
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Fig. 11. Antibody-directed and co,np/ement-medialed cell injury of
glomerular epithelial cells in culture. The degree of cell damage was
assessed by the decline in the incorporation of 3H-leucine when
compared to cells pre-incubated with the antibody and heat-inactivated
serum (100% incorporation). The bars represent average values ob-
tained in six culture dishes (± sEM). Monoclonal antibody K35/31 is of
the lgG2 subclass, directed at a cell surface antigen present exclusively
on glomerular epithelial cells. K35/4 (lgG2a), K9/9 (lgG1), and K35/64
(IgG,) are specific for the 115/107 kd epithelial cell antigen.
the experimental animal. The other two monoclonal antibodies
of the lgG2 isotype, K35/9 and K35/3 I, with specificities for
gp330 and for an unrelated glomerular epithelial cell antigen,
respectively, also revealed in vitro complement binding capac-
ity but did not show nephrotoxicity in the intact animal.
A direct effect of K9/9 on cultures of glomerular epithelial
cells was not detected by direct microscopic observation. When
such cultures were exposed successively to an antibody and a
source of complement, only K35/4 and K35/31 produced cellu-
lar dysfunction that led to a reduction in the rate of 3H-leucine
incorporation (Fig. II). The rate of amino acid incorporation
was reduced to 66% for K3514 and to 77% for K35131 when
compared to the values obtained with heat-inactivated serum
(100%). Monoclonal antibodies K919 and K35/64 did not induce
cell damage as evidenced by the rate of amino acid incorpora-
tion. The relative amounts of immunoglobulin bound to the
cells, determined by a radioimmunoassay, are illustrated in
Figure 12. As depicted in Figures 11 and 12, the amount of
antibody bound to the cells alone did not correlate with the
degree of metabolic dysfunction.
Discussion
We have previously reported on the specific interaction of the
non-complement binding monoclonal antibody (K9/9) with its
specific antigen in the glomerular capillary wall of the rat. The
antigenic complex is found in several epithelia and has an
apparent molecular weight of 115/107 kd [13]. In the experimen-
tal animal, this interaction results in glomerular dysfunction
characterized by glomerular visceral epithelial cell effacement
and proteinuria. The functional abnormality is elicited only
when complete Freund's adjuvant is administered concurrently
with an intravenous injection of the antibody. The structural
and functional changes are antigen specific, since antibodies
deposited in similar quantities in the matrix of the basement
membrane (anti-laminin antibodies) or on endothelial and epi-
flr
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Fig. 12. Antibody-binding to glomerular epithelial cells in culture.
Cells were incubated with a monoclonal antibody for 1 hour, washed,
and then incubated for one hour with 251 affinity purified, rabbit
anti-mouse immunoglobulin. Nonspecific binding was determined for
unreactive monoclonal antibodies of IgGi and IgG isotypes and
subtracted from the isotype-matched experimental values. Bars repre-
sent average values obtained in triplicate (± SEM).
thelial cells (antibodies directed against a 129/I 17 kd cell surface
component) do not induce such abnormalities [13]. In the
present study, we demonstrate that this antibody-induced dys-
function is epitope-specific.
Of three monoclonal antibodies specific for the 115/107 kd
antigen, only one, K9/9, induces morphological and functional
glomerular alterations in vivo. The differences in immunochem-
ical characteristics among the three antibodies, specifically, the
capacity to activate complement and the rate of association and
dissociation from the antigen, do not offer a rational explanation
for the lack of nephrotoxicity of the two monoclonal antibodies,
K35/4 and K35/64. Both these monoclonal antibodies exhibit a
somewhat faster association rate than K9/9, while the relative
dissociation rates of K9/9 and K35/64 are similar and somewhat
slower than that seen for K35/4. Therefore, an unequivocal
nexus between nephrotoxicity and antibody affinity is highly
improbable. Similar conclusions were reached by Gomez and
Richman [26], who reported that the pathogenic potential of
monoclonal antibodies directed at the acetylcholine receptor
was not proportional to the avidity of the antibody for the
antigen in an experimental model of myasthenia gravis.
The glomerular injury induced in vivo by K9/9 is not medi-
ated by complement activation since this antibody does not
activate this system on tissue sections of renal cortex or
following binding to cultured glomerular or proximal tubule
epithelial cells. Deposition of complement components did not
occur in the experimental animals injected with K9/9 when
examined by direct immunofluorescence microscopy. In con-
trast, K35/4, of the IgG2a subclass, was capable of mediating
complement-dependent lysis of established cultures of glomer-
ular and proximal tubule epithelial cells, yet this monoclonal
antibody did not induce significant cellular alterations upon
binding to the glomerular capillary wall in vivo. Rat C3 was not
demonstrable in the kidneys of rats injected with K3514. This
finding would suggest either a lack of complement activation
capacity of this antibody in the intact animal, a rather unlikely
possibility in light of our in vitro results, or in vivo activation of
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complement components in amounts insufficient to be detected
by direct immunofluorescence microscopy. The inability of this
complement-binding monoclonal antibody to induce glomerular
changes in the experimental animal further emphasizes the
unique nature of the interaction between K9/9 and its specific
cell surface antigenic site. These findings suggest that the
mechanism underlying the epithelial cell abnormality induced
by K919 could be of critical relevance in the pathogenesis of
proteinuric conditions, since it appears to be significantly more
effective and sensitive in vivo for disease induction than the
antibody-directed (K3514) and possibly complement-mediated
injury involving the same antigen. Such a complement-medi-
ated mechanism of damage of the glomerular epithelial cell has
clearly been established in other models of immune complex
glomerular diseases [3, 4].
The non-nephritogenic monoclonal antibodies K35/4 and
K35/64 recognize different epitopes on the cell surface antigens,
as determined by competitive radioimmunoassays and by im-
munoblots. These two antibody preparations do not induce
glomerular injury upon in vivo administration, even though the
level of glomerular bound immunoglobulin exceeded that seen
in proteinuric animals injected with K9/9. We hypothesize that
the epitopes recognized by K35/4 and K35/64 are adjacent to
and flank the site recognized by K9/9, since there is reciprocal
blocking between K9/9 and K35/4 and between K9/9 and
K35/64, but there is no blocking effect apparent between K35/4
and K35/64. Moreover, only K9/9 binds to the denatured
protein on Western blots following SDS-polyacrylamide gel
electrophoresis of the solubilized cell membrane preparation, a
finding that favors the idea that K9/9 recognizes a distinct
antigenic site on the protein.
The exact cellular mechanism responsible for the glomerular
alterations induced by monoclonal antibody K9/9 in vivo re-
mains unknown. A direct interference of the monoclonal anti-
body with a cell surface component involved in cell-to-cell or
cell-to-matrix contact could account for the changes described
above. Imhof et al [27, 28] described perturbations of cell-to-
cell adhesion secondary to a loss of tight junctions, with
deletion of cell polarity, uncoupling of adjoining cells, changes
in cell shape, and elaboration of cell surface microvilli in
epithelial cell monolayers derived from canine kidneys (MDCK
cells) upon exposure to a unique monoclonal antibody that
recognizes a 130/40 kd protein. This antigen, which appears to
be related to uvomorulin [281, is normally concentrated at the
level of the cell junctions, but it has also been detected on the
apical surface in cultured cells before they reach confluence. A
mechanism involving perturbation of cell-to-cell contacts by the
antibody is less likely to have caused the glomerular epithelial
cell changes following K9/9 binding in our animal experiments,
given the uniform distribution of the antigen on the luminal side
of epithelial cells rather than a more discrete localization to the
site of cell contacts, as has been demonstrated for uvomorulin.
Epitope specific interactions are also known to occur between
cells of different origin, and functional and non-functional sites
on molecules involved in lymphocyte adhesion to endothelium
and fibroblasts have recently been identified by epitope-specific
monoclonal antibodies [29, 301.
A direct effect on glomerular epithelial cell function could
also have resulted from conformation changes of a cell surface
protein following the binding of an antibody. Histocompatibility
antigens are known to undergo three-dimensional rearrange-
ment after the binding of monoclonal antibodies. Such a "struc-
tural adaptability" may endow these molecules with the "func-
tional versatility" necessary to interact with many different
antigens and T cell receptors [311. Likewise, investigators
working with the HPB-ALL tumor cell line [32] showed that the
binding of monoclonal antibodies to the CD3/Ti complex,
associated with the T cell receptor, induced an epitope specific
increase in intracellular calcium. Changes in calcium influx
precede T cell activation, and are thought to occur as the result
of a conformational change of the extracellular component of
the T cell receptor following the binding of antigen or a specific
antibody for the receptor.
The very unique epitope-specificity of the glomerular epithe-
hal cell alterations seen with K9/9 suggests that the antibody
might be binding to the active site of a receptor, an enzyme, or
a molecule involved in transcellular solute exchange. Cell
changes resulting from interactions between monoclonal anti-
bodies and cell surface receptors are not unprecedented.
Schreiber Ct al [33] described cell shape changes in the epithelial
cell line A431 exposed to a monoclonal antibody directed
against the 170 kd epidermal growth factor (EGF) receptor. The
authors reported changes induced by the monoclonal antibody
that mimic, in part, the effects of the growth factor on A431
cells in culture [34, 351. Similarly, agonist-like effects have been
reported by Baldwin, Terris and Steiner [361 for anti-insulin
receptor antibodies. Since a close structural, biochemical, and
functional association of the EGF receptor with the elements of
the cytoskeleton has been demonstrated [37—39], growth factor-
induced alterations in cell structure and dynamics via changes
in the organization of membrane-associated microfilaments are
likely to occur. The possibility that SGP-l 15/107 represents a
cell surface enzyme or a transport protein cannot be ruled out.
However, the organ and tissue distribution of the antigen and its
molecular weight do not correspond to any cell surface compo-
nent with an established cell function [40—47].
It is conceivable that the 115/107 kd antigen, described by us
in the present communication, is a receptor for a growth factor
and that the monoclonal antibody K9/9 mimics in part some of
the effects of such a factor on the glomerular visceral epithelial
cell. In this regard, it is appropriate to note that experimental
and human glomerulopathies that exhibit simplification and
retraction of foot processes are conditions in which toxic
[48—52] or complement-induced epithelial cell damage occur [3,
4]. In such situations, factors that induce cell replication and
growth would probably be produced systemically or released
locally by damaged cells, and the epithelial cells are likely to be
stimulated to regenerate. Furthermore, podocyte simplification
and retraction has been observed invariably during nephron
hypertrophy secondary to subtotal loss of functioning renal
parenchyma [1, 53] in which a causal agent of direct epithelial
cell injury is not apparent. Therefore, it is tempting to speculate
that an increase in growth-stimulating activity may be a com-
mon factor present in all glomerulopathies that display morpho-
logical alterations of the visceral epithehium that results in an
increased protein excretion rate. Glomerular podocyte retrac-
tion and simplification may result as a direct or indirect conse-
quence of such a stimulus on this highly differentiated epithelial
cell which is known to have retained only a very limited
capacity for cell replication [54, 55]. A monoclonal antibody
Mendrick and Rennke: Epitope-specjfic glo,nerular cell injury 841
directed at the ligand binding site of such a growth factor can be
anticipated to induce some of the effects of the agonist as
described for other cell systems.
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